BRPI0407533A - proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas - Google Patents

proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas

Info

Publication number
BRPI0407533A
BRPI0407533A BRPI0407533-1A BRPI0407533A BRPI0407533A BR PI0407533 A BRPI0407533 A BR PI0407533A BR PI0407533 A BRPI0407533 A BR PI0407533A BR PI0407533 A BRPI0407533 A BR PI0407533A
Authority
BR
Brazil
Prior art keywords
improved properties
interferon
proteins
interferon alpha
alpha fusion
Prior art date
Application number
BRPI0407533-1A
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Marian Hanlon
Francis J Carr
Original Assignee
Merck Patent Ges Mit Beschaenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschaenk filed Critical Merck Patent Ges Mit Beschaenk
Publication of BRPI0407533A publication Critical patent/BRPI0407533A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PROTEìNAS DE FUSãO E MUTEìNAS DO INTERFERON ALFA COM PROPRIEDADES MELHORADAS". A presente invenção refere-se ao interferon alfa humano e em particular a formas modificadas do interferon alfa 2 com propriedades melhoradas. As proteínas melhoradas contêm substituições de aminoácidos em posições específicas que conferem maior atividade relativa nos ensaios biológicos. A invenção fornece ainda interferon alfa modificado com atividade biológica melhorada concomitante com um potencial imunogênico reduzido na proteína. As proteínas melhoradas são pretendidas para uso terapêutico no tratamento de doenças em seres humanos.
BRPI0407533-1A 2003-02-18 2004-02-18 proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas BRPI0407533A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003647 2003-02-18
PCT/EP2004/001524 WO2004074486A2 (en) 2003-02-18 2004-02-18 Fusion proteins of interferon alpha muteins with improved properties

Publications (1)

Publication Number Publication Date
BRPI0407533A true BRPI0407533A (pt) 2006-02-14

Family

ID=32892853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407533-1A BRPI0407533A (pt) 2003-02-18 2004-02-18 proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas

Country Status (11)

Country Link
US (1) US7456257B2 (pt)
EP (1) EP1594965A2 (pt)
JP (1) JP2007524351A (pt)
KR (1) KR20050107435A (pt)
CN (1) CN1751122A (pt)
AU (1) AU2004213565A1 (pt)
BR (1) BRPI0407533A (pt)
CA (1) CA2516293A1 (pt)
MX (1) MXPA05008704A (pt)
PL (1) PL376673A1 (pt)
WO (1) WO2004074486A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
AU2006263331B2 (en) * 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US9891225B2 (en) * 2013-05-10 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of HCV antigen/antibody
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用
CN117717604A (zh) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
EP3955957A1 (en) 2019-04-15 2022-02-23 Qwixel Therapeutics LLC Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
CN116162171B (zh) 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997033998A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
RU2262510C9 (ru) * 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
US20060062761A1 (en) * 2001-03-02 2006-03-23 Carr Francis J Modified interferon alpha with reduced immunogenicity
EP1512004B1 (en) * 2002-06-11 2006-03-15 MERCK PATENT GmbH Method for mapping and eliminating t-cell epitopes
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1581631A4 (en) * 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES

Also Published As

Publication number Publication date
CN1751122A (zh) 2006-03-22
MXPA05008704A (es) 2005-10-05
KR20050107435A (ko) 2005-11-11
WO2004074486A2 (en) 2004-09-02
US7456257B2 (en) 2008-11-25
US20070148739A1 (en) 2007-06-28
EP1594965A2 (en) 2005-11-16
WO2004074486A3 (en) 2005-03-31
JP2007524351A (ja) 2007-08-30
AU2004213565A1 (en) 2004-09-02
CA2516293A1 (en) 2004-09-02
PL376673A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
MXPA02006679A (es) Composicion farmaceutica.
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
BRPI0407001A (pt) Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica
CR7875A (es) Variantes de inmunoglobina y usos de esto
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
MX2022008748A (es) Administración oral de péptidos.
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber
AR042019A1 (es) N-acetilgalactosamina-4-sulfatasa precursora, composiciones farmaceuticas que la contienen , metodos de tratamiento que la utilizan y metodos para producirla y purificarla
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
DE50009838D1 (de) Humanes antibiotisches protein
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired